Advertisement
Advertisement
U.S. markets open in 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Annexon, Inc. (ANNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.94-0.19 (-3.10%)
At close: 04:00PM EDT
5.89 -0.05 (-0.84%)
After hours: 04:49PM EDT
Advertisement

Annexon, Inc.

1400 Sierra Point Parkway
Building C Suite 200
Brisbane, CA 94005
United States
650 822 5500
https://www.annexonbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees75

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas Love J.D., Esq.CEO, Pres & Director830.99kN/A1968
Dr. Larry C. Mattheakis Ph.D.Exec. VP & Chief Scientific Officer296.45kN/A1957
Dr. Ted Yednock Ph.D.Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board614.6kN/A1958
Dr. Arnon Rosenthal Ph.D.FounderN/AN/A1956
Ms. Jennifer LewExec. VP & CFON/AN/A1973
Miriam MasonSr. VP of Corp. CommunicationsN/AN/AN/A
Mr. Michael Overdorf M.B.A.Exec. VP & Chief Bus. OfficerN/AN/A1970
Henk-Andre Kroon M.D.Sr. VP of Translational MedicineN/AN/AN/A
Mirella Villa Del ToroSec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Corporate Governance

Annexon, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement